Phenylpropanone modulators of dopamine receptor
AssigneeAuspex Pharmaceuticals, Inc.
InventorsThomas G. Gant, Manouchehr M. Shahbaz, Sepehr Sarshar
Life of this patent
Estimating the term…
Abstract
The present invention relates to new phenylpropanone modulators of dopamine receptors, serotonin receptors, and/or nicotinic acetylcholine receptors, pharmaceutical compositions thereof, and methods of use thereof.
Claims51
A compound of structural Formula I
- or a salt thereof, wherein:
- R1-R18 are independently selected from the group consisting of hydrogen and deuterium;
- at least one of R1-R18 is deuterium;
- if R12-R14 are each deuterium, at least one of R1-R11 and R15-R18 is deuterium;
- and
- if R1-R9 are each deuterium, at least one of R10-R18 is deuterium.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a compound of structural Formula I
- or a salt thereof, wherein:
- R1-R18 are independently selected from the group consisting of hydrogen and deuterium;
- and
- at least one of R1-R18 is deuterium.
A method of treatment of a dopamine receptor-mediated disorder, a serotonin receptor-mediated disorder, or a nicotinic acetylcholine receptor-mediated disorder comprising the administration, to a patient in need thereof, of a therapeutically effective amount of a compound of structural Formula I
- or a salt thereof, wherein:
- R1-R18 are independently selected from the group consisting of hydrogen and deuterium;
- and
- at least one of R1-R18 is deuterium.
A compound, for use as a medicament, of structural Formula I
- or a salt thereof, wherein:
- R1-R18 are independently selected from the group consisting of hydrogen and deuterium;
- and
- at least one of R1-R18 is deuterium.
A compound, for use in the manufacture of a medicament for the prevention or treatment of a disorder ameliorated by the modulation of dopamine receptors, serotonin receptors, or nicotinic acetylcholine receptors, of structural Formula I
- or a salt thereof, wherein:
- R1-R18 are independently selected from the group consisting of hydrogen and deuterium;
- and
- at least one of R1-R18 is deuterium.
A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
- wherein R1-R18 are independently selected from H and D;
- and
- the abundance of deuterium in R1-R18 is at least 6%.
An isolated deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
- wherein R1-R18 are independently selected from H and D;
- and
- the abundance of deuterium in R1-R18 is at least 6%.
A mixture of deuterium-enriched compounds of formula I or a pharmaceutically acceptable salt thereof:
- wherein R1-R18 are independently selected from H and D;
- and
- the abundance of deuterium in R1-R18 is at least 6%.
Dependencies are inferred from the claim text.